News Between Reporter

Upon further analysis of the study conducted by Jeffrey Cohen, MD, it was found that clinical and radiologic measures of disease activity remained stable or improved for relapsing multiple sclerosis (RMS) patients of all age groups over a period of 7 to 8 years of continuous treatment with ozanimod (Zeposia). Regardless of the age category,